Send to

Choose Destination
J Pediatr Hematol Oncol. 2020 Feb 6. doi: 10.1097/MPH.0000000000001720. [Epub ahead of print]

Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.

Author information

Departments of Pediatric Hematology and Oncology.
Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan.
Clinical Laboratory, Hyogo Prefectural Amagasaki General Medical Center, Hyogo.


Secondary expansion and/or evolution of aggressive subclones are associated with the disease progression and resistance to chemotherapy in neuroblastoma, and it is important to track the clonal changes during the treatment period. Cell-free (cf) DNA analysis, namely liquid biopsy, can detect the genomic change of tumor cells without surgical procedures. In this report, we showed that serial polymerase chain reaction-based cf DNA neuroblastoma proto-oncogene quantification is sensitive enough to evaluate the aggressive cellular characteristics of ALK/MYCN-coamplified neuroblastoma and stressed the promise of cf DNA analyses as a reliable molecular marker in advanced neuroblastoma.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center